Monaco Asset Management SAM Sells 260,218 Shares of Q32 Bio Inc. $QTTB

Monaco Asset Management SAM reduced its position in shares of Q32 Bio Inc. (NASDAQ:QTTB) by 83.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,919 shares of the company’s stock after selling 260,218 shares during the quarter. Monaco Asset Management SAM owned 0.41% of Q32 Bio worth $169,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in QTTB. Marshall Wace LLP bought a new stake in Q32 Bio during the second quarter worth $25,000. Acadian Asset Management LLC bought a new stake in Q32 Bio during the first quarter worth $50,000. Two Sigma Investments LP bought a new stake in Q32 Bio during the third quarter worth $62,000. AQR Capital Management LLC bought a new position in shares of Q32 Bio in the first quarter valued at about $68,000. Finally, Jane Street Group LLC bought a new position in shares of Q32 Bio in the second quarter valued at about $69,000. 31.32% of the stock is owned by institutional investors.

Q32 Bio Price Performance

Shares of QTTB opened at $11.05 on Monday. The firm has a market capitalization of $187.41 million, a PE ratio of 4.15 and a beta of 0.26. The company’s 50-day moving average is $6.35 and its 200-day moving average is $4.66. Q32 Bio Inc. has a fifty-two week low of $1.35 and a fifty-two week high of $13.15. The company has a debt-to-equity ratio of 0.04, a current ratio of 5.36 and a quick ratio of 5.36.

Q32 Bio (NASDAQ:QTTB) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.14. Equities analysts forecast that Q32 Bio Inc. will post -1.96 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on QTTB shares. Weiss Ratings raised shares of Q32 Bio from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 11th. Mizuho started coverage on shares of Q32 Bio in a research report on Friday, May 22nd. They issued an “outperform” rating and a $14.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $13.00 price objective on shares of Q32 Bio in a research report on Tuesday, May 5th. Cantor Fitzgerald started coverage on shares of Q32 Bio in a research report on Monday, May 18th. They issued an “overweight” rating on the stock. Finally, Zacks Research lowered shares of Q32 Bio from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 18th. Three analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $13.50.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.